5th Mar 2018 07:00
Silence Therapeutics to Present at the Cowen 38th Annual Health Care Conference
London, 5th March 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that Ali Mortazavi, Chief Executive Officer, will present at the Cowen 38th Annual Health Care Conference on Tuesday, 13 March, 2018 at 10:30am EDT in Boston, MA.
The presentation will be webcast live and may be accessed by visiting Silence's website at http://www.silence-therapeutics.com/investors/. A replay of the webcast will be available for 14 business days.
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer | Tel: +44 (0)20 3457 6900 |
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
|
Tel: +44 (0)20 7418 8900 |
Media Enquiries: Optimum Strategic Communications Mary Clark/ Eva Haas/Hollie Vile
|
Tel: +44 (0) 20 3714 1788 |
IR Enquires - US Burns McClellan John Grimaldi | Tel: +1 (212) 213 0006 |
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/
Related Shares:
SLN.L